A

    Avita Medical Ltd (RCEL)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $10.10
    -0.25 (-2.42%)

    Market Cap: $312.36M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(14/28)
    Avg Surprise
    -33.76%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.29
    Range$-0.37 - $-0.23
    4 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.34-14.7%
    60d ago$-0.38-30.1%
    30d ago$-0.35-19.8%
    7d ago$-0.29-0.3%
    Current$-0.29
    Revenue Consensus
    $32M
    Range$31M - $32M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.26
    Range$-0.45 - $0.07
    4 analysts
    Revenue Consensus
    $37M
    Range$35M - $39M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.26---
    Sep 26EST
    		-$-0.29---
    Jun 26
    Reported Aug 6
    		$-0.25$-0.39+35.90%Beat+34.2%
    Mar 26
    Reported May 14
    		$-0.48$-0.38-26.32%Miss+42.2%
    Dec 25
    Reported Feb 12
    		$-0.54$-0.55+1.82%Beat+22.7%
    Sep 25
    Reported Nov 6
    		$-0.71$-0.45-57.78%Miss-14.5%
    Jun 25
    Reported Aug 7
    		$-0.38$-0.26-46.15%Miss+58.2%
    Mar 25
    Reported May 8
    		$-0.83$-0.51-62.75%Miss+24.5%
    Dec 24
    Reported Feb 13
    		$-0.70$-0.74+5.97%Beat-62.4%
    Sep 24
    Reported Nov 7
    		$-0.62$-0.44-40.91%Miss-17.0%
    Jun 24
    Reported Aug 8
    		$-0.91$-0.76-19.74%Miss-44.4%
    Mar 24
    Reported May 13
    		$-1.10$-0.73-50.68%Miss-100.0%
    Dec 23
    Reported Feb 22
    		$-0.43$-0.57+24.56%Beat-38.7%
    Sep 23
    Reported Nov 9
    		$-0.53$-0.68+22.06%Beat-60.6%
    Jun 23
    Reported Aug 10
    		$-0.63$-0.46-36.96%Miss-80.0%
    Mar 23
    Reported May 11
    		$-0.55$-0.36-52.78%Miss+0.0%
    Dec 22
    Reported Feb 23
    		$-0.31$-0.41+24.39%Beat+8.8%
    Sep 22
    Reported Nov 10
    		$-0.33$-0.51+35.29%Beat-37.5%
    Jun 22
    Reported Aug 11
    		$-0.35$-0.57+38.60%Beat-105.9%
    Mar 22
    Reported May 12
    		$-0.55$-0.52-5.77%Miss-61.8%
    Dec 21
    Reported Feb 28
    		$-0.34$-0.37+7.76%Beat+0.0%
    Sep 21
    Reported Nov 8
    		$-0.24$-0.38+36.84%Beat+63.6%
    Jun 21
    Reported Aug 26
    		$-0.17$-0.29+41.38%Beat+71.7%
    Mar 21
    Reported May 13
    		$-0.34$-0.50+32.00%Beat+52.1%
    Dec 20
    Reported Feb 11
    		$-0.34$-0.59+42.37%Beat-413.6%
    Sep 20
    Reported Nov 10
    		$-0.66$-0.49-34.69%Miss-
    Jun 20
    Reported Aug 27
    		$-0.60$-0.24-150.00%Miss-
    Mar 20
    Reported Apr 29
    		$-0.71$-0.09-688.89%Miss-
    Dec 19
    Reported Feb 18
    		$-0.07$-0.03-120.67%Miss-
    Sep 19
    Reported Oct 31
    		$0.00N/A+100.00%Beat-
    Jun 19
    Reported Aug 29
    		$0.00$0.00N/ABeat-
    Mar 19
    Reported May 21
    		$0.00$0.00N/ABeat-
    Dec 18
    Reported Feb 27
    		$0.00$0.00N/ABeat-
    Sep 18
    Reported Oct 30
    		$0.00$0.00N/ABeat-
    Jun 18
    Reported Aug 30
    		$0.00$0.00N/ABeat-
    Mar 18
    Reported Apr 29
    		$0.00$0.00N/ABeat-
    Dec 17
    Reported Jan 30
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-5.10EV/EBITDA-6.17x
    Price/FCF-12.26xFCF Yield-8.15%
    Profitability
    Profit Margin-57.00%Operating Margin-31.60%
    ROE-1746.00%ROIC-172.56%
    Financial Health
    Debt/Equity-1.78xInterest Coverage-6.97x
    Current Ratio0.41xQuick Ratio0.34x
    Trading Statistics
    Beta1.85Avg Volume752.97K
    52-Week High$10.7752-Week Low$3.22

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.21
    SMA 20$8.57
    SMA 50$6.14
    SMA 200$4.62
    EMA 10$9.83
    EMA 20$8.78
    EMA 50$6.94
    EMA 200$5.34

    MACD

    Line: 1.36Signal: 1.32Hist: 0.04

    ADX

    ADX: 51.4+DI: 36.2-DI: 10.3

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down16.0
    PSAR$9.24

    Bollinger Bands

    Upper Band$12.61
    Lower Band$4.53
    %B Position9432%(Upper)
    Band Width0.69

    RSI (14-Day)

    Overbought
    72.6

    Momentum Oscillators

    Stoch %K84.1
    Stoch %D89.0
    Williams %R-21.5
    ROC (10d)27.8%
    Momentum2.20
    CCI (20d)65.3
    MFI (14d)84.5

    Volatility Measures

    ATR (14d)$0.65(6.5%)
    StdDev (20d)2.02
    Hist Vol241.5%(High)

    Volume Flow

    VWAP$10.08
    OBV19.0M
    AD Line12.1M
    CMF (20d)0.436

    Volume Metrics

    Avg Vol (20d)785.8K
    Vol Ratio0.2x(Low)
    VWMA (20d)$8.35

    Pivot Points

    R3$11.12
    R2$10.88
    R1$10.62
    Pivot Point$10.38
    S1$10.12
    S2$9.88
    S3$9.62

    Advanced Oscillators

    TSI55.80
    Ultimate Osc57.0
    KST1056.72

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$21.70M$19.25M$17.62M$17.06M$18.42M$18.51M$18.41M$19.55M$15.20M$11.10M$14.20M$13.64M
    Cost of Revenue$3.94M$3.52M$3.31M$3.19M$3.47M$2.83M$2.28M$3.19M$2.11M$1.51M$1.80M$2.11M
    Gross Profit$17.77M$15.73M$14.31M$13.88M$14.95M$15.68M$16.13M$16.36M$13.08M$9.59M$12.40M$11.53M
    Operating Expenses$24.62M$24.53M$24.72M$23.03M$26.10M$27.51M$26.08M$30.16M$28.71M$26.80M$24.67M$20.84M
    R&D$5.08M$5.63M$5.69M$3.75M$5.12M$6.28M$4.85M$5.43M$4.89M$5.19M$6.76M$4.39M
    SG&A$5.97M$6.06M$7.09M$7.23M$6.67M$6.39M$7.12M$9.59M$7.52M$8.96M$7.75M$6.12M
    Operating Income$-6,855,000$-8,803,000$-10,406,000$-9,153,000$-11,148,000$-11,827,000$-9,957,000$-13,806,000$-15,624,000$-17,206,000$-12,273,000$-9,306,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$1.46M$1.42M$1.25M$1.27M$1.25M$1.23M$1.30M$1.36M$1.35M$1.36M$1.12M$10,000
    Income Before Tax$-7,630,000$-10,622,000$-11,637,000$-13,172,000$-9,916,000$-13,851,000$-11,570,000$-16,233,000$-15,360,000$-18,628,000$-7,053,000$-8,701,000
    Income Tax Expense$33,000$-11,000$-16,000$15,000$4,000$8,000$19,000$-28,000$33,000$30,000$12,000$11,000
    Net Income$-7,663,000$-10,611,000$-11,621,000$-13,187,000$-9,920,000$-13,859,000$-11,589,000$-16,205,000$-15,393,000$-18,658,000$-7,065,000$-8,712,000
    EBITDA$-5,605,000$-8,648,000$-9,770,000$-11,361,000$-8,177,000$-12,225,000$-10,057,000$-14,891,000$-14,284,000$-17,746,000$-6,245,000$-8,615,000
    EBIT$-6,167,000$-9,198,000$-10,386,000$-11,904,000$-8,664,000$-12,618,000$-10,271,000$-14,874,000$-14,013,000$-17,272,000$-5,931,000$-8,691,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RCEL

    News

    AVITA Medical (RCEL) CFO boosts direct stake to 152,927 shares

    AVITA Medical (RCEL) CFO David D. O'Toole amended a previous insider transaction, reporting the purchase of 2,000 shares of common stock at $3.97 per share on June 12, 2026. This amendment corrected the transaction code from "A" to "P". Following this purchase, O'Toole's directly held position, including unvested RSUs, totals 152,927 shares.

    Stock Titan•8/24/26•
    Somewhat-Bullish

    Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?

    Avita Medical Inc. (RCEL) is identified as a strong momentum stock with a Zacks Rank of #2 (Buy) and a Momentum Style Score of B. The article highlights RCEL's significant short-term price increases, outperforming its industry and the S&P 500, along with positive earnings estimate revisions. These factors suggest it could be a promising pick for investors looking for near-term growth.

    Yahoo Finance•8/24/26•
    Bullish

    Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft

    A new study on Avita Medical's PermeaDerm product demonstrated a 70% reduction in treatment costs compared to cadaveric allografts for temporary wound coverage. The PermeaDerm-I study, a randomized controlled trial involving 40 patients across 11 burn centers, also showed comparable healing and safety results, alongside significant reductions in preparation time due to simpler logistics. Surgeons highlighted PermeaDerm's ease of use, transparency, and predictable supply chain as advantages over allograft, with favorable outcomes even in large TBSA burns.

    TradingView•8/19/26•
    Bullish

    TD Cowen raises Avita Medical stock price target on PermeaDerm data

    TD Cowen has increased its price target for Avita Medical (NASDAQ:RCEL) to $14.00 from $12.00, maintaining a Buy rating, citing enhanced confidence in PermeaDerm's commercial potential after positive clinical trial data and surgeon endorsements. The stock has surged 185% year-to-date, trading near its 52-week high, while recent financial reports also showed Avita Medical exceeding revenue estimates in Q2.

    Investing.com•8/19/26•
    Bullish

    Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft

    A new study by Avita Medical demonstrated that its PermeaDerm product reduced treatment costs by 70% compared to cadaveric allograft for temporary wound coverage, costing $148.70 versus $497.10 per 1% of total body surface area treated. The biosynthetic wound matrix also significantly cut preparation time while showing comparable graft take, application time, and eight-week wound healing outcomes. Surgeons noted PermeaDerm's standardized design, easier logistics, and potential use in larger burns, highlighting its transparency and consistent supply.

    Yahoo Finance•8/19/26•
    Bullish

    Frequently Asked Questions About RCEL

    Does RCEL pay dividends?
    Avita Medical Ltd (RCEL) does not currently pay a regular dividend.
    What is RCEL's market cap?
    Avita Medical Ltd (RCEL) has a market capitalization of $312.36M with a current stock price of $10.10.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In